Sleep formulation comparison
Magnesium Glycinate vs L-Threonate for Sleep: What the Evidence Supports
Both formulation families now have direct human sleep trials. That makes the comparison more interesting—but it still does not create a proven winner, because the trials used different products, populations, durations, outcomes, and funding structures rather than comparing the forms head to head.
Bottom line
Two direct evidence programs, zero direct form-vs-form trials
Magnesium bisglycinate: a 2025 randomized trial enrolled 155 adults with self-reported poor sleep and studied 250 mg elemental magnesium daily for four weeks. Insomnia Severity Index scores improved slightly more than placebo, but the effect was small (Cohen d=0.2) and objective sleep was not measured.
Magnesium L-threonate: placebo-controlled trials in 80 adults for 21 days and 100 adults for six weeks studied branded Magtein. The 2024 trial’s later corrigendum clarified retrospective registration and substantial AIDP sponsor/author ties; the 2026 trial found some subjective and cognitive signals without a general objective sleep-outcome advantage. Neither trial compared L-threonate directly with glycinate or bisglycinate.
Evidence Snapshot
Evidence: LimitedMagnesium bisglycinate / glycinate
- Human evidence
- The most direct recent trial randomized 155 adults ages 18–65 with self-reported poor sleep to 250 mg elemental magnesium as bisglycinate or placebo daily for four weeks. The insomnia-severity difference was statistically significant but small (d=0.2), and objective sleep was not measured.
- Research signal
- Glycine-related calming claims and general magnesium physiology are plausible hypotheses, but they do not prove that glycinate is the best sleep form or that one bedtime dose works acutely.
- Safety profile
- Supplemental magnesium can cause diarrhea, nausea, and cramping. Toxicity risk rises with impaired kidney function, and magnesium can interfere with absorption of oral bisphosphonates and tetracycline/quinolone antibiotics.
Evidence Snapshot
Evidence: LimitedMagnesium L-threonate
- Human evidence
- A 2024 trial studied 80 adults ages 35–55 with self-assessed sleep problems for 21 days using 1 g/day branded Magtein; a newer trial studied 100 adults ages 18–45 with dissatisfied sleep for six weeks using 2 g/day Magtein. These are separate branded-product trials rather than head-to-head evidence against glycinate, and the 2026 study did not show a general objective sleep-outcome advantage.
- Research signal
- Claims about brain magnesium and blood-brain-barrier delivery are mechanistic rationale, not proof that L-threonate produces superior sleep outcomes.
- Safety profile
- A 2025 corrigendum clarified that the 2024 trial was retrospectively registered; AIDP commissioned and funded it, owns relevant patents, and three authors had paid, consulting, or company roles. The newer trial received funding from Threotech. These conflicts do not automatically invalidate results, but they materially affect how branded-product evidence should be generalized.
What the direct trials actually compared
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Evidence | Population / regimen | Signal | Main limit |
|---|---|---|---|
| Bisglycinate RCT, 2025 | 155 adults, ages 18–65, poor self-reported sleep; 250 mg elemental magnesium daily vs placebo for 4 weeks. | Greater ISI reduction than placebo; small effect, d=0.2. | No objective sleep measure; does not establish superiority over other magnesium forms or an acute bedtime effect. |
| L-threonate RCT, 2024 | 80 adults, ages 35–55, self-assessed sleep problems; 1 g/day Magtein vs placebo for 21 days. | Several subjective and Oura-derived sleep/daytime outcomes favored Magtein. | Short branded-product study. The 2025 corrigendum reports retrospective registration, AIDP commissioning/funding and patent ownership, and three authors with paid, consulting, or company roles. |
| L-threonate RCT, 2026 | 100 adults, ages 18–45, dissatisfied sleep; 2 g/day Magtein vs placebo for 6 weeks. | Some cognitive and subjective sleep-related outcomes favored Magtein; objective wearable sleep outcomes did not show a general between-group advantage. | Branded Magtein evidence; study received funding from Threotech and does not establish overall sleep superiority over other forms. |
Why “glycinate wins” is not evidence-based
There is no randomized sleep trial assigning people to magnesium glycinate or bisglycinate versus magnesium L-threonate. Cost, capsule burden, elemental-magnesium labeling, and personal tolerability may affect a purchase, but those are practical considerations—not evidence that one form treats sleep better.
The same caution applies to trial dosing. A four-week bisglycinate regimen and 21-day or six-week L-threonate regimens describe what researchers tested. They do not create a universal evening dose, a first-night rescue instruction, or a reason to combine both forms.
Check before using
Magnesium safety and medication boundaries
- Kidney function: magnesium toxicity risk rises when renal clearance is impaired; significant kidney disease deserves clinician review before supplementation.
- GI effects: supplemental magnesium can cause diarrhea, nausea, and abdominal cramping.
- Bisphosphonates: magnesium can reduce absorption of oral bisphosphonate medicines.
- Antibiotics: magnesium can reduce absorption of tetracycline and quinolone antibiotics; medication spacing should follow pharmacist/prescriber instructions.
- Total exposure: combining magnesium forms increases total supplemental magnesium. Do not treat two different salt names as two unrelated supplements.
Chronic insomnia is a treatment question, not a magnesium-form contest
CBT-I is the first-line evidence-based treatment for chronic insomnia. Loud snoring or gasping, dangerous daytime sleepiness, restless-legs symptoms, persistent impairment, or severe mood symptoms are reasons to seek assessment rather than escalating magnesium forms.
Product sourcing note
This broad form comparison intentionally does not rank affiliate products. The strongest direct L-threonate evidence is tied to branded Magtein, while the bisglycinate trial studied a defined elemental-magnesium exposure. A retail label is not automatically equivalent to a study preparation, and a branded trial is not proof that a whole form wins.
Frequently asked questions
Is magnesium glycinate or L-threonate better for sleep?
No head-to-head sleep trial has established one as better. Magnesium bisglycinate has a 155-person four-week placebo-controlled trial with a small insomnia-severity effect. Magnesium L-threonate has placebo-controlled trials in 80 and 100 adults, but those studies used branded Magtein and had industry funding. These are separate evidence programs, not a direct comparison.
Does magnesium glycinate work the first night?
The direct 2025 bisglycinate trial studied daily supplementation for four weeks. It did not test an as-needed bedtime rescue dose, so it cannot establish a reliable first-night effect.
Does magnesium L-threonate cross the blood-brain barrier better?
Brain-bioavailability claims are part of the mechanistic rationale for L-threonate, but mechanism does not prove superior sleep outcomes. The clinically useful question is whether a formulation improves meaningful sleep outcomes in people, and there is still no head-to-head sleep trial against glycinate or bisglycinate.
What dose should I take for sleep?
This comparison does not prescribe a universal dose. Trial regimens describe what researchers tested, not what every reader should take. Elemental magnesium exposure also differs substantially across magnesium salts and commercial products.
Can I combine magnesium glycinate and L-threonate?
There is no sleep evidence showing that taking both forms together is more effective or safer. Combining them also increases total supplemental magnesium exposure and makes side effects or benefits harder to attribute.
What should I do if insomnia is chronic?
CBT-I is the first-line evidence-based treatment for chronic insomnia. Persistent sleep problems also warrant evaluation for causes such as sleep apnea, restless legs, circadian disorders, medication effects, mood disorders, substance use, pain, or insufficient sleep opportunity.
Sources and directness notes
- 1. Magnesium bisglycinate randomized placebo-controlled trial (2025) — 155 adults ages 18–65 with self-reported poor sleep received 250 mg elemental magnesium as bisglycinate or placebo daily for four weeks. The insomnia-severity difference favored bisglycinate but was small (Cohen d=0.2). The study did not include an objective sleep measure.
- 2. Magnesium L-threonate randomized trial (2024) — 80 adults ages 35–55 with self-assessed sleep problems received 1 g/day branded Magtein or placebo for 21 days. Several subjective and Oura-derived outcomes favored L-threonate. A later corrigendum clarified important registration and sponsor disclosures.
- 3. Corrigendum to the 2024 magnesium L-threonate trial (2025) — The corrigendum states that the trial was retrospectively registered and clarifies that AIDP commissioned and funded the study, owns patents related to the product, and that three authors had paid, consulting, or company roles with AIDP. These disclosures are part of the trial’s interpretation context.
- 4. Magnesium L-threonate randomized trial (2026) — 100 adults ages 18–45 with dissatisfied sleep received 2 g/day branded Magtein or placebo for six weeks. Some cognitive and subjective sleep-related outcomes favored treatment, but sleep-disturbance/restorative-sleep measures and objective wearable sleep outcomes did not show a general between-group advantage. The study received funding from Threotech.
- 5. Oral magnesium supplementation for insomnia systematic review (2021) — Only three randomized trials / 151 older adults were included. Evidence quality was low to very low, underscoring how thin the broader insomnia literature was before the newer formulation-specific trials.
- 6. NIH ODS: Magnesium health professional fact sheet — Supplemental magnesium can cause gastrointestinal effects, toxicity risk rises with impaired kidney function, and magnesium can reduce absorption of oral bisphosphonates and tetracycline/quinolone antibiotics.
- 7. AASM: cognitive behavioral therapy for insomnia — AASM describes CBT-I as the first-line, evidence-based treatment for chronic insomnia.
Free safety checklist
Get future sleep evidence notes by email
New trials, safety context, and evidence-calibrated guide updates without universal winner or dosing claims.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Newsletter
Continue with the newsletter archive
Short research notes for cautious supplement decisions.
Last evidence review: 2026-08-12